stockrow
Friday 6 November 2026
Export ACB’s income statement to Excel — free account
Aurora Cannabis Inc.
ACB Healthcare Drug Manufacturers Specialty & Generic
Aurora Cannabis Inc.’s revenue for fiscal 2026 (year ended March 2026) was $232.0 million, down 5.95% from fiscal 2025.
- Revenue
- −31.2%
- EPS
- +75.0%
- Free cash flow
- −293.6%
- Total debt
- −82.5%
Quarter to June 2026, against a year earlier
5.23
0.04
+0.77%
Follow ACB
Alert me
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
0.00 | 0.00 | 0.00 | 0.00 |
P/S ratio |
1.28 | 0.90 | 0.80 | 0.82 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(11.49) | 19.22 | (733.60) | (53.59) | |
P/B ratio |
0.82 | 0.59 | 0.50 | 0.45 | |
Price to Tangible BV |
0.92 | 0.66 | 0.56 | 0.51 | |
EV/Sales |
1.15 | 0.74 | 0.53 | 0.58 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
185.39 | (28.81) | (12.65) | (5.95) | |
EV/FCF |
(25.01) | (9.25) | (4.89) | (3.35) | |
Quick Ratio |
1.52 | 1.36 | 3.13 | 2.59 | |
Current Ratio |
3.41 | 3.06 | 5.94 | 5.36 | |
Net Debt/EBITDA |
4.15 | (9.14) | 13.80 | 34.68 | |
Debt/Assets |
12.52% | 12.25% | 3.02% | 2.71% | |
Debt/Equity |
0.17 | 0.17 | 0.04 | 0.03 | |
Asset Turnover |
0.46 | 0.46 | 0.44 | 0.40 | |
Operating CF/Net income |
0.78 | 9.54 | 0.01 | 1.10 | |
Capex/Depreciation |
(0.78) | (1.22) | 8.65 | (1.10) | |
Interest Coverage |
(8.37) | 1.04 | 2.33 | (18.82) | |
Research and Development Expense of Revenue |
1.00% | 1.38% | 2.57% | 3.75% | |
Selling, General and Administrative Expense of Revenue |
51.75% | 42.54% | 107.67% | 60.52% | |
Intangible Assets out of Total Assets |
0.08 | 0.08 | 0.10 | 0.10 | |
Share Based Compensation of Revenue |
5.51% | 2.35% | (5.37%) | 1.03% | |
Graham Net Nets |
0.51 | 0.71 | 1.20 | 1.26 | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(12.42%) | (26.78%) | (47.71%) | (50.54%) | |
Free Cash Flow Yield |
(3.59%) | (8.89%) | (13.64%) | (20.98%) | |
Revenue per Share |
1.16 | 1.19 | 0.49 | 0.79 | |
Operating CF per Share |
(0.52) | 0.22 | 0.00 | (0.05) | |
Capex per Share |
(0.07) | (0.07) | (0.07) | (0.06) | |
Free Cash Flow per Share |
(0.59) | 0.15 | (0.08) | (0.12) | |
Cash per Share |
1.83 | 1.95 | 2.10 | 1.75 | |
Shareholders Equity per Share |
7.29 | 7.18 | 6.53 | 6.17 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
7.29 | 7.18 | 6.53 | 6.17 | |
Free Cash Flow |
(33.37) | 8.67 | (4.28) | (7.12) | |
Working Capital |
217.57 | 215.12 | 239.23 | 231.15 | |
Capital Expenditures |
(4.08) | (3.78) | (4.03) | (3.91) | |
Net Current Asset Value |
169.92 | 170.98 | 223.07 | 216.48 | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.06 | 0.06 | 0.14 | 0.08 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
31.68 | 33.53 | 31.39 | 28.99 | |
Average Payables |
32.22 | 49.38 | 44.76 | 49.91 | |
Average Inventory |
158.33 | 173.40 | 149.28 | 150.25 | |
Average Assets |
571.12 | 587.49 | 523.94 | 527.11 | |
Average Common Equity |
419.49 | 422.34 | 403.93 | 403.18 |
Columns are period end dates · fundamentals updated 2 Nov 2026